Huang Chunling, Zou Weikang, Ma Wenbei, Li Jiali, Bai Yichen, Wu Rong, Li Qiqi, Fang Qi, Chen Wenna, Lu Xiaohe, Feng Songfu
Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, No. 253, Gongye Avenue Middle, Guangzhou, 510282, Guangdong, China.
Eur J Med Res. 2025 Jan 28;30(1):55. doi: 10.1186/s40001-024-02206-7.
To evaluate the effect and factors associated with the reactivation of retinopathy of prematurity (ROP) after intravitreal conbercept or aflibercept.
We retrospectively reviewed the medical records of 176 eyes diagnosed with ROP and treated with anti-VEGF therapy between January 2018 and September 2022. The rate of reactivation and complications were assessed during the follow-up period. The factors of reactivation of ROP after intravitreal conbercept or aflibercept were analyzed on the basis of clinical factors and retinal parameters.
Reactivation of ROP occurred in 10 eyes (13.9%) after intravitreal conbercept and 13 eyes (12.5%) after intravitreal aflibercept (P = 0.79). The interval between injection and reactivation was significantly longer in the aflibercept group than in the conbercept group (15.50 ± 4.05 vs. 5.36 ± 0.50 weeks) (P < 0.001). The central retinal arteriolar equivalent (CRAE) of aggressive ROP was larger than that of type 1 prethreshold and threshold ROP before anti-VEGF therapy (P < 0.05). Zone I and stage 3 exhibited a positive correlation with the reactivation of retinopathy of prematurity (ROP) [odds ratio (OR) = 20.15, 5.02]. The changes in CRAE of pre-and post-therapy and gestational age were identified as potential protective factors for these outcomes (OR = 0.23, 0.49).
Conbercept and aflibercept are effective for treating ROP. Aflibercept resulted in longer treatment intervals compared to conbercept. Zone, stage, and gestational age were associated with the reactivation of ROP. CRAE was associated with not only the severity of ROP but also its reactivation. Additionally, it may be an objective indicator in the early indication and follow-up of ROP.
评估玻璃体内注射康柏西普或阿柏西普后早产儿视网膜病变（ROP）复发的影响及相关因素。
我们回顾性分析了2018年1月至2022年9月期间176只诊断为ROP并接受抗VEGF治疗的眼睛的病历。在随访期间评估复发率和并发症。基于临床因素和视网膜参数分析玻璃体内注射康柏西普或阿柏西普后ROP复发的因素。
玻璃体内注射康柏西普后10只眼（13.9%）发生ROP复发，玻璃体内注射阿柏西普后13只眼（12.5%）发生复发（P = 0.79）。阿柏西普组注射至复发的间隔时间显著长于康柏西普组（15.50 ± 4.05 vs. 5.36 ± 0.50周）（P < 0.001）。抗VEGF治疗前，侵袭性ROP的视网膜中央动脉等效直径（CRAE）大于1型阈值前期和阈值期ROP（P < 0.05）。I区和3期与早产儿视网膜病变（ROP）复发呈正相关[优势比（OR） = 20.15，5.02]。治疗前后CRAE的变化和胎龄被确定为这些结果的潜在保护因素（OR = 0.23，0.49）。
康柏西普和阿柏西普治疗ROP有效。与康柏西普相比，阿柏西普的治疗间隔时间更长。区域、分期和胎龄与ROP复发有关。CRAE不仅与ROP的严重程度有关，还与其复发有关。此外，它可能是ROP早期诊断和随访的客观指标。
